IE
IBRX icon

Israel Englander’s ImmunityBio IBRX Stock Holding History

Israel Englander’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,800
Closed -$183K – 6096
2026
Q1 		$183K Buy
+23,800
New +$163K ﹤0.01% 5213
2024
Q2 		– Sell
-350,000
Closed -$1.88M – 6179
2024
Q1 		$1.88M Buy
+350,000
New +$1.58M ﹤0.01% 3799

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Israel Englander's IBRX Position: Q2 2026 in Review

Israel Englander increased its ImmunityBio (IBRX) stake by 293% in Q2 2026, buying an estimated $31.5M and bringing the position to 5,579,793 shares worth $48.9M. The position accounts for 0.02% of the portfolio, ranked #905.

Israel Englander first reported a position in IBRX in Q1 2016 and has held it in 37 quarters since. 402 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Israel Englander held 5,579,793 shares of ImmunityBio worth $48.9M as of Q2 2026.
  • Israel Englander bought 4,159,549 ImmunityBio shares in Q2 2026, an estimated $31.5M.
  • ImmunityBio made up 0.02% of Israel Englander's portfolio in Q2 2026, its #905 holding.
  • Israel Englander first reported a position in ImmunityBio in Q1 2016 and has held it in 37 quarters since.
  • 402 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.